FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912451311> ?p ?o ?g. }

• W2912451311 endingPage "286" @default.
• W2912451311 startingPage "283" @default.
• W2912451311 abstract "BACKGROUND: Vitiligo is an acquired pigmentary disease, that causes progressive loss of melanocytes, resulting in hypopigmented skin patches. Current treatments aim at stopping the disease progression and achieving repigmentation of the amelanotic areas. Corticosteroids, surgery, topical immunomodulators, total depigmentation of normal pigmented skin and phototherapy are current treatment options for vitiligo although phototherapy remains the treatment of choice. There is no documented evidence that herbal bio-active products may also be effective treatment options for vitiligo.&#x0D; AIM: This study aimed to investigate the efficacy and safety of Vitilinex® (herbal bio- actives) alone and in combination with UVB narrowband (311 nm) phototherapy, in the treatment of localised stable or active forms of vitiligo.&#x0D; MATERIAL AND METHODS: Sixty two subjects with mean age 34.5 years (range: 18-58 years) with mild to moderate vitiligo, consisting of 36 females and 26 males were randomly divided into three treatment groups – Group A (13 females, 10 males ) treated with Vitilinex® alone; Group B (12 females, 11 males) were treated with Vitilinex® in combination with narrowband UVB (311 nm) phototherapy for 15 seconds, using a handheld lamp and Group C (8 females, 8 males ) were treated with nbUVB (311 nm) phototherapy alone, for 15 seconds over a 12-week period.&#x0D; RESULTS: In Group A, 9 patients (39%) achieved outstanding improvement with a re-pigmentation rate higher than 75%, with 2 patients experiencing total repigmentation. 6 patients (26%) had marked improvement with a repigmentation rate between 50-75% while 5 patients (22%) showed a moderate response between 25-50% re-pigmentation rate. 3 patients (13%) had minimal or no improvement. In Group B, 16 patients (69.5%) achieved outstanding improvement with a re-pigmentation rate higher than 75%, with 12 patients experiencing total re-pigmentation. 4 patients (17.5 %) achieved a marked improvement with a re-pigmentation rate between 50-75%; 2 patients (8.7%) showed a moderate response with a re-pigmentation rate between 25-50%. 1 (4.3%) patient had minimal or no improvement. In Group C, 6 patients (37.5%) achieved a re-pigmentation rate higher than 75%, with 2 patients experiencing total re-pigmentation. 4 patients (25%) achieved marked improvement with a re-pigmentation rate between 50-75% while 3 patients (18.75%) had a re-pigmentation rate between 25-50%. 3 patients (18.75%) had minimal or no improvement.&#x0D; CONCLUSION: Vitilinex® herbal bio-actives in combination with nbUVB is a more effective treatment option for vitiligo with 87% of the patients achieving a re-pigmentation rate higher than 50%, compared to Vitilinex® alone (65%) or nbUVB alone (62.5%)." @default.
• W2912451311 created "2019-02-21" @default.
• W2912451311 creator A5001950150 @default.
• W2912451311 creator A5003189317 @default.
• W2912451311 creator A5005325429 @default.
• W2912451311 creator A5016063877 @default.
• W2912451311 creator A5020469299 @default.
• W2912451311 creator A5021432996 @default.
• W2912451311 creator A5029144480 @default.
• W2912451311 creator A5030948693 @default.
• W2912451311 creator A5037326193 @default.
• W2912451311 creator A5065966132 @default.
• W2912451311 creator A5077303657 @default.
• W2912451311 creator A5077906350 @default.
• W2912451311 creator A5083973504 @default.
• W2912451311 creator A5087525638 @default.
• W2912451311 creator A5087777376 @default.
• W2912451311 creator A5090110058 @default.
• W2912451311 date "2019-01-28" @default.
• W2912451311 modified "2023-10-16" @default.
• W2912451311 title "Successful Treatment of Vitiligo Vietnamese Patients with Vitilinex® Herbal Bio-Actives in Combination with Phototherapy" @default.
• W2912451311 cites W1899351010 @default.
• W2912451311 cites W1981684826 @default.
• W2912451311 cites W2030082674 @default.
• W2912451311 cites W2043930391 @default.
• W2912451311 cites W2047270627 @default.
• W2912451311 cites W2055539585 @default.
• W2912451311 cites W2059119358 @default.
• W2912451311 cites W2084021290 @default.
• W2912451311 cites W2101577055 @default.
• W2912451311 cites W2119694038 @default.
• W2912451311 cites W2168580009 @default.
• W2912451311 cites W2469468793 @default.
• W2912451311 cites W2627050665 @default.
• W2912451311 cites W2785368803 @default.
• W2912451311 cites W2785741518 @default.
• W2912451311 cites W2786134102 @default.
• W2912451311 cites W2786211708 @default.
• W2912451311 cites W2786504283 @default.
• W2912451311 cites W2786887850 @default.
• W2912451311 cites W2787266286 @default.
• W2912451311 cites W2787739631 @default.
• W2912451311 cites W2811054971 @default.
• W2912451311 cites W2996278023 @default.
• W2912451311 doi "https://doi.org/10.3889/oamjms.2019.095" @default.
• W2912451311 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6364738" @default.
• W2912451311 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30745981" @default.
• W2912451311 hasPublicationYear "2019" @default.
• W2912451311 type Work @default.
• W2912451311 sameAs 2912451311 @default.
• W2912451311 citedByCount "3" @default.
• W2912451311 countsByYear W29124513112022 @default.
• W2912451311 countsByYear W29124513112023 @default.
• W2912451311 crossrefType "journal-article" @default.
• W2912451311 hasAuthorship W2912451311A5001950150 @default.
• W2912451311 hasAuthorship W2912451311A5003189317 @default.
• W2912451311 hasAuthorship W2912451311A5005325429 @default.
• W2912451311 hasAuthorship W2912451311A5016063877 @default.
• W2912451311 hasAuthorship W2912451311A5020469299 @default.
• W2912451311 hasAuthorship W2912451311A5021432996 @default.
• W2912451311 hasAuthorship W2912451311A5029144480 @default.
• W2912451311 hasAuthorship W2912451311A5030948693 @default.
• W2912451311 hasAuthorship W2912451311A5037326193 @default.
• W2912451311 hasAuthorship W2912451311A5065966132 @default.
• W2912451311 hasAuthorship W2912451311A5077303657 @default.
• W2912451311 hasAuthorship W2912451311A5077906350 @default.
• W2912451311 hasAuthorship W2912451311A5083973504 @default.
• W2912451311 hasAuthorship W2912451311A5087525638 @default.
• W2912451311 hasAuthorship W2912451311A5087777376 @default.
• W2912451311 hasAuthorship W2912451311A5090110058 @default.
• W2912451311 hasBestOaLocation W29124513111 @default.
• W2912451311 hasConcept C141071460 @default.
• W2912451311 hasConcept C16005928 @default.
• W2912451311 hasConcept C2776291823 @default.
• W2912451311 hasConcept C2776972258 @default.
• W2912451311 hasConcept C2779980618 @default.
• W2912451311 hasConcept C71924100 @default.
• W2912451311 hasConceptScore W2912451311C141071460 @default.
• W2912451311 hasConceptScore W2912451311C16005928 @default.
• W2912451311 hasConceptScore W2912451311C2776291823 @default.
• W2912451311 hasConceptScore W2912451311C2776972258 @default.
• W2912451311 hasConceptScore W2912451311C2779980618 @default.
• W2912451311 hasConceptScore W2912451311C71924100 @default.
• W2912451311 hasIssue "2" @default.
• W2912451311 hasLocation W29124513111 @default.
• W2912451311 hasLocation W29124513112 @default.
• W2912451311 hasLocation W29124513113 @default.
• W2912451311 hasLocation W29124513114 @default.
• W2912451311 hasOpenAccess W2912451311 @default.
• W2912451311 hasPrimaryLocation W29124513111 @default.
• W2912451311 hasRelatedWork W1993377052 @default.
• W2912451311 hasRelatedWork W2070078678 @default.
• W2912451311 hasRelatedWork W2119278097 @default.
• W2912451311 hasRelatedWork W2149529261 @default.
• W2912451311 hasRelatedWork W2596339367 @default.
• W2912451311 hasRelatedWork W2901970500 @default.
• W2912451311 hasRelatedWork W2903627030 @default.
• W2912451311 hasRelatedWork W4225311958 @default.

• next